Previous studies revealed that certain integrins expressed on endothelial cells play a significant role in the progression of angiogenesis and are an attractive target for the development of angiostatic drugs that may have an application in the therapy of various tumors. Using immunohistochemistry we detected the expression of a9?1 integrin on endothelial cells forming blood capillaries in all organs of the body, and an up-regulation of its level in certain tumors including gliomas. However, following isolation the majority of primary endothelial cells in the culture stop expressing a9?1 integrin. This sensitivity of a9?1 integrin on endothelial cells in vitro was the reason that researchers never considered this integrin as an important receptor for modulation of the neovascularization process, especially during oncogenesis. In the proposed research plan we will investigate a role for this integrin in angiogenesis following its interaction with thrombospondin-1 (TSP-1), in the context of brain tumor vascularization. Recently, we evaluated that TSP-1 is a ligand for a9?1 integrin, which has a binding site on the N-terminal (NoC1) domain of this extracellular matrix protein. Based on previously published work that TSP-1 is up-regulated during brain tumor progression, we proposed a general hypothesis that the interaction of a9?1 with TSP-1 is an important element of pathological angiogenesis occurring during diffusive glioma development. To verify this hypothesis we propose a series of experiments in vitro and in vivo that may lead to an explanation of a9?1 integrin's and TSP-1's role in the promotion of pathological angiogenesis induced in brain tumors. We will isolate a9?1 integrin-positive primary glioma human microvascular endothelial cells (gHMVEC) from cancer tissue obtained following surgery, by immuno-sorting in first passage cells expressing this integrin and typical endothelial cell markers such as CD31. We will investigate pro-angiogenic activities of these cells such as proliferation and migration, induced by TSP-1 and its recombinant NoC1 domain, as well as evaluate the signaling pathway that is activated inside the cell in these processes. We will confirm our expectation that the interaction of a9?1 with TSP-1 extensively occurs on endothelial cells during glioma progression using double fluorescent color immunohistochemistry of paraffin sections obtained from normal brain and different grades of astrocyte-derived tumors. In animal experiments, we intend to prove that the blocking of a9?1 integrin by a specific monoclonal antibody or by a MLD-disintegrin, VLO5 will suppress the development of experimental glioma by blocking the vascularization process. Also, we will transfect glioma cells with the NoC1 domain and we expect to observe a higher ratio of tumor growth following intracranial implantation of these transfectants into rats. In another part of the study, we will perform a structure/function analysis of the NoC1 domain to localize the a9?1 integrin binding site on TSP-1. This work will be performed by chemical synthesis of peptides spanning the N-terminal module of the NoC1 domain and by site-directed mutagenesis of recombinant fragments of this part of TSP-1. We will investigate the up-regulation of NoC1-like domain in clinical and experimental glioma tissues in comparison with normal brain using a specific monoclonal antibody, 2D11 that recognizes NoC1 in Western blot. Further, the structural characterization of tumoral NoC1-like domain will be performed using proteomic approaches.
Glioma is one of the most frequently occurring and difficult to treat brain tumors. This tumor belongs to the most vascularized cancers and angiostatic treatment, which will block vessel growth in pathological tissue, appears to be effective in its therapy. In this context, we propose an investigation a receptor, a9?1 integrin that is present on the endothelial cells, which are the major structural cells in vessel wall. Investigation of this receptor may be beneficial for cancer as well as for cardiovascular disease having patients, because regulation of vascularization process is important in these pathologies.
|Momic, Tatjana; Katzhendler, Jehoshua; Shai, Ela et al. (2015) Vipegitide: a folded peptidomimetic partial antagonist of Î±2Î²1 integrin with antiplatelet aggregation activity. Drug Des Devel Ther 9:291-304|
|Lecht, Shimon; Chiaverelli, Rachel A; Gerstenhaber, Jonathan et al. (2015) Anti-angiogenic activities of snake venom CRISP isolated from Echis carinatus sochureki. Biochim Biophys Acta 1850:1169-79|
|Ventresca, Erin M; Lecht, Shimon; Jakubowski, Piotr et al. (2015) Association of p75(NTR) and Î±9Î²1 integrin modulates NGF-dependent cellular responses. Cell Signal 27:1225-36|
|Marcinkiewicz, Cezary (2013) Applications of snake venom components to modulate integrin activities in cell-matrix interactions. Int J Biochem Cell Biol 45:1974-86|
|Jakubowski, Piotr; Calvete, Juan J; Eble, Johannes A et al. (2013) Identification of inhibitors of Î±2Î²1 integrin, members of C-lectin type proteins, in Echis sochureki venom. Toxicol Appl Pharmacol 269:34-42|
|Ettinger, Keren; Lecht, Shimon; Arien-Zakay, Hadar et al. (2012) Nerve growth factor stimulation of ERK1/2 phosphorylation requires both p75NTR and Ã½Ã½9Ã½Ã½1 integrin and confers myoprotection towards ischemia in C2C12 skeletal muscle cell model. Cell Signal 24:2378-88|
|Walsh, Erin M; Kim, Richard; Del Valle, Luis et al. (2012) Importance of interaction between nerve growth factor and Ã½Ã½9Ã½Ã½1 integrin in glial tumor angiogenesis. Neuro Oncol 14:890-901|
|Carbajo, Rodrigo J; Sanz, Libia; Mosulen, Silvia et al. (2011) NMR structure and dynamics of recombinant wild type and mutated jerdostatin, a selective inhibitor of integrin Ã½Ã½1Ã½Ã½1. Proteins 79:2530-42|
|Walsh, Erin M; Marcinkiewicz, Cezary (2011) Non-RGD-containing snake venom disintegrins, functional and structural relations. Toxicon 58:355-62|
|Lecht, Shimon; Arien-Zakay, Hadar; Wagenstein, Yoav et al. (2010) Transient signaling of Erk1/2, Akt and PLCgamma induced by nerve growth factor in brain capillary endothelial cells. Vascul Pharmacol 53:107-14|
Showing the most recent 10 out of 12 publications